For investors in Singapore

Horizon Biotechnology Fund

A fund investing in innovative companies addressing high unmet medical needs or improving the standard of care in the fast-growing biotechnology sector.

ISIN
LU1988887292

NAV
SGD 19.05
As of 2023/09/27

1-Day Change
SGD 0.20 (1.06%)
As of 2023/09/27

Morningstar Rating

As of 2023/08/31

Overview

INVESTMENT OBJECTIVE

The Fund aims to provide capital growth over the long term.

More

The Fund invests at least 80% of its assets in shares (equities) and equity-related securities of companies, which are biotechnology or biotechnology-related, in any country.

Less

Note: You should not make investment decisions based solely on marketing materials. You should read the Prospectus and the Product Highlights Sheet of the Fund for more details of the investment risks and seek independent professional advice where appropriate.

ABOUT THIS FUND

Experienced and Specialised Investment Team: Dedicated biotechnology specialists with deep scientific backgrounds and a distinguished record of investing in biotechnology stocks. This highly specialised team is supported by the larger Janus Henderson health care team with over a century of combined health care investing experience.

Differentiated Fundamental Research: Seek to understand the science and the business to identify opportunities and mitigate the clinical and commercial risks inherent in the sector.

Disciplined Investment Process: Balanced across development stage, early commercial and profitable biotechnology companies and augmented by a differentiated Value at Risk Framework designed to mitigate the volatility associated with drug development.

TOP HOLDINGS

Top holdings can be found in the factsheet of the fund.

PORTFOLIO MANAGEMENT

Andy Acker, CFA

Portfolio Manager

Industry since 1996. Joined Firm in 1999.

Daniel Lyons, Ph.D., CFA

Portfolio Manager | Research Analyst

Industry since 2000. Joined Firm in 2000.

Agustin Mohedas, Ph.D.

Portfolio Manager | Research Analyst

Industry since 2014.

Performance

Discrete Performance (%)
As of 2023/06/30
A2 SGD (Net)
 
Quarter End
As of 2023/06/30
Jun-2022 - Jun-2023 Jun-2021 - Jun-2022 Jun-2020 - Jun-2021 Jun-2019 - Jun-2020 Jun-2018 - Jun-2019
A2 SGD (Net) 46.55 -29.61 30.66 - -
Cumulative & Annualised Performance (%)
As of 2023/08/31
A2 SGD (Net) NASDAQ Biotechnology Total Return
 
  Cumulative Annualised
1MO 3MO 6MO YTD 1YR 3YR 5YR 10YR Since Inception
2019/09/13
A2 SGD (Net) 1.87 2.56 14.22 13.49 32.70 10.47 - - 18.50
NASDAQ Biotechnology Total Return 1.46 0.90 1.74 -1.11 3.98 -0.63 - - 6.24
Calendar Year Returns (%)
As of 2023/06/30
A2 SGD (Net) NASDAQ Biotechnology Total Return
2022 2021 2020
A2 SGD (Net) -4.32 -1.96 59.12
NASDAQ Biotechnology Total Return -10.58 2.03 24.26
FEE INFORMATION
Initial Charge 5.00%
Annual Charge 1.20%
Ongoing Charge
(As of 2022/06/30)
1.86%
Performance Fee 20% of the 'Relevant Amount'
Hurdle Rate NASDAQ Biotechnology Total Return Index

Documents